|
1
|
Thompson LD: Osteosarcoma. Ear Nose Throat
J. 92:288–290. 2013.PubMed/NCBI
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT,
Xia YJ, Ye ZY and Tao HQ: MicroRNA-101 is down-regulated in gastric
cancer and involved in cell migration and invasion. Eur J Cancer.
46:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang JG, Guo JF, Liu DL, Liu Q and Wang
JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small
cell lung cancer through directly targeting enhancer of zeste
homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He XP, Shao Y, Li XL, Xu W, Chen GS, Sun
HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101
in gastric cancer correlates with cyclooxygenase-2 overexpression
and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang Z, Huo L, Li K, Wu Y and Hu Z:
Blocked autophagy by miR-101 enhances osteosarcoma cell
chemosensitivity in vitro. Scientific World Journal.
7947562014.PubMed/NCBI
|
|
11
|
Zhang K, Zhang Y, Ren K, Zhao G, Yan K and
Ma B: MicroRNA-101 inhibits the metastasis of osteosarcoma cells by
downregulation of EZH2 expression. Oncol Rep. 32:2143–2149.
2014.PubMed/NCBI
|
|
12
|
Lin S, Shao NN, Fan L, Ma XC, Pu FF and
Shao ZW: Effect of microRNA-101 on proliferation and apoptosis of
human osteosarcoma cells by targeting mTOR. J Huazhong Univ Sci
Technolog Med Sci. 34:889–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, et al:
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation,
invasion and stem cell-like phenotype of aggressive endometrial
cancer cells. Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frankel LB, Wen J, Lees M, Høyer-Hansen M,
Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent
inhibitor of autophagy. EMBO J. 30:4628–4641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lei Y, Li B, Tong S, Qi L, Hu X, Cui Y, Li
Z, He W, Zu X, Wang Z and Chen M: miR-101 suppresses vascular
endothelial growth factor C that inhibits migration and invasion
and enhances cisplatin chemosensitivity of bladder cancer cells.
PLoS One. 10:e01178092015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y
and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular
carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer
Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu
C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses
SOX9-dependent tumorigenicity and promotes favorable prognosis of
human hepatocellular carcinoma. FEBS Lett. 586:4362–4370. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo F, Cogdell D, Hu L, Yang D, Sood AK,
Xue F and Zhang W: MiR-101 suppresses the epithelial-to-mesenchymal
transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol
Rep. 31:2021–2028. 2014.PubMed/NCBI
|
|
20
|
Caputto BL, Gizzi Cardozo AM and Gil GA:
c-Fos: An AP-1 transcription factor with an additional cytoplasmic,
non-genomic lipid synthesis activation capacity. Biochim Biophys
Acta. 1841:1241–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gamberi G, Benassi MS, Bohling T,
Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M,
Magagnoli G, Balladelli A and Picci P: C-myc and c-fos in human
osteosarcoma: Prognostic value of mRNA and protein expression.
Oncology. 55:556–563. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van den Berg S, Rahmsdorf HJ, Herrlich P
and Kaina B: Overexpression of c-fos increases recombination
frequency in human osteosarcoma cells. Carcinogenesis. 14:925–928.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang ZQ, Liang J, Schellander K, Wagner EF
and Grigoriadis AE: c-fos-induced osteosarcoma formation in
transgenic mice: Cooperativity with c-jun and the role of
endogenous c-fos. Cancer Res. 55:6244–6251. 1995.PubMed/NCBI
|
|
24
|
Liang X, Liu Y, Zeng L, Yu C, Hu Z, Zhou Q
and Yang Z: miR-101 inhibits the G1-to-S phase transition of
cervical cancer cells by targeting Fos. Int J Gynecol Cancer.
24:1165–1172. 2014. View Article : Google Scholar : PubMed/NCBI
|
